Featured Listing

AlphaMaven

Company Logo'

Venture Capital Featured Listing

BrookDell Partners

Back

Venture Capital

Andrea Alms Video:  Money In Motion 31 - Deep Tech Vertical - Biotech

November 2022 - Venture Capital

posted by BrookDell Partners

TRANSCRIPT:


Hello. My name is Andrea Alms. I am technology investor and financial manager and this is your money in motion. On the previous episode we discussed what is deep tech. Today we are focusing on AI, artificial intelligence, deep tech in biotechnology. Remember, deep tech technology is a catch all phrase for innovative technologies that potentially offer significant advances over those currently used. Thus, this area is attracting an unprecedented level of investment in attempts to move these technologies into the marketplace. We searched the data so far. This is all we could find up to 2018. Why? From 2015 to 2018, disclose us private investments in seven major deep tech sectors grew on average 22% per year, with biotechnologies disclosing almost 19 billion artificial intelligence almost 15 billion of total investments in 2018. Quantum computing also made the list at 123 million. This 2018 data is remember, this is 2018 data and we will dig more in future episodes. This Data Room com blog report shows that deep tech startups follow a different growth trajectory than other tech startups. Deep tech startups have longer R&D cycles and take more time and capital to build than regular startups. But despite the higher perceived risk and deep tech startups are no more likely to fail than tech companies and have roughly the same, if not slightly higher, exit probabilities. For example, deep tech breakthroughs are set to define a generation's worth of innovation. Germany based biotech company Biontech created the first ever RNA based vaccine used to combat COVID 19. There journey though extraordinary an impact an outcome was typical of a tech startup spun out of a university. They received EU funding, went through long R&D phases before finally finding transformational technological success and market fit. Remember, successes like Biontech demonstrate the importance of early support from governments and universities. Yes, at the end of the day, it is unicorn hunting, high risk potentially high return, and definitely not for the faint of heart. Please keep this in mind when deep tech investing. Thank you. This is your money. Your money in motion.


ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.